Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
CA 2292902 C · Owner: Universite De Sherbrooke · Inventors: Cadieux, Alain
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of calcitonin gene-related peptide (CGRP) in the prevention and alleviation of asthmatic symptoms. In contrast to other therapeutic agents now in use CGRP combines both , bronchoprotector and anti-inflammatory properties. Furthermore it prevents , both early and late phase bronchial responses associated with an asthma attack and its effective dose is small enough that undesirable haemodynamic side effects are not present.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 24, 1999 and granted December 18, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 24, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 24, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.